Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo

Fig. 1

DFX inhibited the proliferation of pancreatic cancer cell lines. Cell proliferation was measured using the MTS assay after cells were treated with DFX 72 h. The viability of BxPC-3, HPAF-II, and Panc 10.05 cells incubated with DFX decreased in a dose-dependent manner. The data are presented as the mean ± SD (n = 3–5). *p <0.05, **p <0.01 vs. control

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us